adagrasib
mirati
['lcsm,(-blcsm)', 'improve', 'adagrasib']
#lcsm starting strong #asco22 adagrasib in kras g12c - large number of responses, decent enough duration of response. looking forward to having more options for patients. future with combinations will hopefully improve response rates and duration 
Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition